ReviewFrontiers in oncology2015
Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy.
Review in Frontiers in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 48 citations in OpenAlex.
- Epithelioid Sarcoma: A Review and Update.Cancers · 2026Review
- Epithelioid Sarcoma of the Forearm in a 70-Year-Old Woman: A Case Report at a Referral Facility in Tanzania.Clinical case reports · 2026Article
- Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers.Journal of hematology & oncology · 2024Review
- Translational Aspects of Epithelioid Sarcoma: Current Consensus.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Review
- Synchronous Double Primary Angiosarcoma Originating from the Stomach and Rectum: A Case Report and a Literature Review.Archives of Iranian medicine · 2024Review
- Review
- Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology.Clinical and translational medicine · 2022Article
- Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments.Biomedicines · 2022Review
- CHIR99021, trough GSK-3β Targeting, Reduces Epithelioid Sarcoma Cell Proliferation by Activating Mitotic Catastrophe and Autophagy.International journal of molecular sciences · 2021Article
- A case of primary distal-type epithelioid sarcoma of the lumbar vertebra with a review of literature.Virchows Archiv : an international journal of pathology · 2021Review
- Epithelioid Sarcoma in a Young Child: A Case Report and Literature Review.Plastic and reconstructive surgery. Global open · 2021Article
- Pazopanib in rare histologies of metastatic soft tissue sarcoma.Ecancermedicalscience · 2021Article
- Diagnosis and management of primary malignant tumors in the upper extremity.Orthopedic reviews · 2020Article
- Epithelioid Sarcoma-From Genetics to Clinical Practice.Cancers · 2020Review
- A metastatic distal-type epithelioid sarcoma: Case report and review.International journal of surgery case reports · 2020Article
- Primary rhabdoid epithelioid sarcoma of the left thigh mimicking epithelioid rhabdomyosarcoma: A diagnostic pitfall.International journal of surgery case reports · 2020Article
- Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma.BMC cancer · 2019Article
- Clinicopathologic features of epithelioid sarcoma: report of seventeen cases and review of literature.International journal of clinical and experimental pathology · 2019Article
- Long period of relative quiescence in distal-type epithelioid sarcoma of the forearm with recurrence after surgery: A case report.Medicine · 2018Article
- Epithelioid sarcoma of the vulva and its clinical implication: A case report and review of the literature.Gynecologic oncology reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelioid sarcoma (ES) is a soft tissue sarcoma of children and young adults for which the preferred treatment for localized disease is wide surgical resection. Medical management is to a great extent undefined, and therefore for patients with regional and distal metastases, the development of targeted therapies is greatly desired. In this review, we will summarize clinically relevant biomarkers (e.g., SMARCB1, CA125, dysadherin, and others) with respect to targeted therapeutic opportunities. We will also examine the role of EGFR, mTOR, and polykinase inhibitors (e.g., sunitinib) in the management of local and disseminated disease. Toward building a consortium of pharmaceutical, academic, and non-profit collaborators, we will discuss the state of resources for investigating ES with respect to cell line resources, tissue banks, and registries so that a roadmap can be developed toward effective biology-driven therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.